Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study
Irma Kluijt(Amsterdam UMC Location University of Amsterdam), Marianthi Tsitlaidou(National Centre of Scientific Research "Demokritos"), Rodney J. Scott(New South Wales Department of Health), Richard Rosenquist(Karolinska University Hospital), Anath Flugelman(Carmel Medical Center), Michael Gilbert(University of Pennsylvania), Tomasz Byrski(International Hereditary Cancer Center), Tomasz Huzarski(International Hereditary Cancer Center), J Kantala(Karolinska University Hospital), Flavio Lejbkowicz(Carmel Medical Center), Antonis C. Antoniou(Weatherford College), Ana Osório(Spanish National Cancer Research Centre), Cora M. Aalfs(University of Amsterdam), H Ozçelik(Mount Sinai Hospital), Irene L. Andrulis(University of Toronto), Javier Benı́tez(Spanish National Cancer Research Centre), M Paligo(Lund University), Anna Jakubowska(Pomeranian Medical University), Gord Glendon(University Health Network), P. Sanchez-Serrano(The Netherlands Cancer Institute), Susan M. Domchek(University City Science Center), Ute Hamann(German Cancer Research Center), Paolo Aretini(Fondazione Pisa), Katherine L. Nathanson(Translational Therapeutics (United States)), Beatrice Melin(Umeå University), Dominik Rozkrut(University of Szczecin), Teresa Ramóny Cajal(Hospital de Sant Pau), Ulf Kristoffersson, Gad Rennert(Technion – Israel Institute of Technology), Matti A. Rookus(The Netherlands Cancer Institute), Per Karlsson(University of Gothenburg), B Aroer(Uppsala University), Jacek Gronwald(International Hereditary Cancer Center), Cezary Cybulski(Kolding Hospital), Mads Thomassen(Odense University Hospital), Niklas Loman(Lund University), S Healy(Lunenfeld-Tanenbaum Research Institute), L McGuffog(Lunenfeld-Tanenbaum Research Institute), Annelie Liljegren(Karolinska University Hospital), Marie Stenmark‐Askmalm(Linköping University), Kenneth D. Herbst, Olga M. Sinilnikova(Hospices Civils de Lyon), Janusz Menkiszak(Pomeranian Medical University), Anna von Wachenfeldt(Karolinska Institutet)
Cited by 38
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k